HolderBook

CHI Advisors LLC

Reported holdings as of Q3 2023, from 17 quarterly filings.

This filer last reported in Q3 2023; the most recent quarter on file across all filers is Q2 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1791468
Reported value
$252.3M
Positions
26
Top 10 weight
81.4%
Filed
2023-11-13
Days after quarter end
44

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
PLIANT THERAPEUTICS INC OPTPLRX$52.3M3,014,19920.74%+3.55pp14q-3.3%-$1.8M
REPARE THERAPEUTICS INC OPTRPTX$36.0M2,966,67414.27%+4.64pp14q-1.1%-$389.0K
CULLINAN THERAPEUTICS INCCGEM$30.9M3,414,18912.25%+1.10pp11qHELD
ACELYRIN INCSLRN$23.0M2,262,9909.12%-7.77pp2q-15.0%-$4.1M
ORCHARD THERAPEUTICS PLCORTX$14.0M12,315,6545.56%+4.37pp3q+1529.6%+$13.2M
LARIMAR THERAPEUTICS INCLRMR$13.5M3,414,4685.35%+2.70pp14qHELD
KEROS THERAPEUTICS INCKROS$13.0M407,6335.15%+0.25pp14q+1.4%+$175.8K
IKENA ONCOLOGY INCIKNA$9.4M2,180,9343.74%-0.48pp11q+2.8%+$255.0K
ULTRAGENYX PHARMACEUTICAL INRARE$7.7M215,0003.04%+1.85pp2q+152.9%+$4.6M
COMPASS THERAPEUTICS INCCMPX$5.6M2,829,7122.21%-0.52pp8qHELD
MINERALYS THERAPEUTICS INCMLYS$5.4M568,3792.14%-newNEW
INOZYME PHARMA INCINZY$5.3M1,270,0272.11%+0.09pp13q+6.3%+$315.0K
SYROS PHARMACEUTICALS INCSYRS$5.1M1,299,3592.03%+1.30pp3q+69.3%+$2.1M
BLUEPRINT MEDICINES CORPBPMC$4.7M92,8881.85%-newNEW
DIREXION SHS ETF TRLABD$4.6M225,0001.84%+0.42pp2q-30.8%-$2.1M
2SEVENTY BIO INCTSVT$3.9M1,002,0071.56%-1.06pp7q+17.6%+$588.0K
MOONLAKE IMMUNOTHERAPEUTICSMLTX$3.4M60,0001.36%-newNEW
OVID THERAPEUTICS INCOVID$3.3M864,8221.32%+0.46pp17qHELD
SAGIMET BIOSCIENCES INCSGMT$3.1M348,8421.22%-newNEW
OMEGA THERAPEUTICS INCOMGAQ$2.3M1,055,8820.90%-0.89pp9qHELD
BLACK DIAMOND THERAPEUTICS IBDTX$2.1M720,0000.82%-0.33pp2q-4.0%-$86.1K
RALLYBIO CORPRLYB$1.3M390,7340.52%-0.41pp5q-28.0%-$512.4K
DISC MEDICINE INCIRON$1.2M25,0000.47%-1.22pp2q-80.0%-$4.7M
GRAPHITE BIO INCGRPH$572.7K230,9380.23%+0.04pp2qHELD
FREELINE THERAPEUTICS HLDGSFRLN$372.6K86,6540.15%+0.13pp2q+300.0%+$279.4K
PRECISION BIOSCIENCES INCDTIL$207.0K606,6290.08%-0.17pp17q-62.2%-$340.3K

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 56.6%Not classified 43.4%
 
SectorValueShare
Biotech & Pharma$142.9M56.6%
Not classified$109.4M43.4%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q3 2023$252.3M26488381.4%44
Q2 2023$329.6M25856686.2%53
Q1 2023$376.7M23478389.7%41
Q4 2022$375.5M22096391.9%44
Q3 2022$371.9M252127385.9%40
Q2 2022$261.8M264131082.8%43
Q1 2022$235.2M222113083.3%46
Q4 2021$301.3M201125086.7%42
Q3 2021$342.6M19147091.5%46
Q2 2021$429.9M18147490.7%42
Q1 2021$499.5M213611391.4%44
Q4 2020$355.0M21249295.8%43
Q3 2020$281.1M21387195.4%43
Q2 2020$256.3M19629096.9%48
Q1 2020$42.4M13155097.0%44
Q4 2019$132.6M12056199.0%45
Q3 2019$102.7M13000097.6%43

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.